Circulating levels of coagulation and inflammation markers and cancer risks: Individual participant analysis of data from three long-term cohorts

International Journal of Epidemiology

Volumn 39, Issue 3, 2010, Pages 699-709

  dos Santos Silva, Isabel ^a   de Stavola, Bianca L ^a   Pizzi, Costanza ^a   Meade, Tom W ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cancer; Coagulation; Fibrinogen; Inflammation; Smoking

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; FIBRINOGEN; PROTHROMBIN;

CANCER; COAGULATION; COHORT ANALYSIS; EPIDEMIOLOGY; HEALTH RISK; RESEARCH WORK; RISK FACTOR; SMOKING;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; DISEASE MARKER; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FOLLOW UP; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SMOKING;

C-REACTIVE PROTEIN; COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FACTOR VIIA; FIBRINOGEN; GREAT BRITAIN; HUMANS; INCIDENCE; LEUKOCYTE COUNT; LUNG NEOPLASMS; MALE; NEOPLASMS; PEPTIDE FRAGMENTS; PROTHROMBIN; SMOKING;

EID: 77955791228     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyq012     Document Type: Article

References (31)

1. Erlinger TP, Muntner P, Helzlsouer KJ. WBC count and the risk of cancer mortality in a national sample of US adults: results from the Second National Health and Nutrition Examination Survey Mortality Study. Cancer Epidemiol Biomark Prev 2004;13:1052-56.
2. Jee SH, Park JY, Kim H-S, Lee T-Y, Samet JM. White blood cell count and risk for all-cause, cardiovascular, and cancer mortality in a cohort of Koreans. Am J Epidemiol 2005;162:1062-69.
3. Il'yasova D, Colbert LH, Harris TB et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomark Prev 2005;14:2413-18.
4. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet 1998;351: 1077-80.
5. Sørensen HT, Mellemkjær L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-73.
6. Everett CJ, Wells BJ, Frithsen IL, Koopman RJ. Smoking, fibrinogen and cancer mortality. J Natl Med Assoc 2007;99: 328-33.
7. Yano K, Grove JS, Chen R et al. Plasma fibrinogen as a predictor of total and cause-specific mortality in elderly Japanese-American men. Artherioscler Thromb Vasc Biolo 2001;21:1065-70.
8. Flossmann E, Rothwell PM. on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13.
9. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953-58.
10. Tagalakis V, Tamim H, Blostein M et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007;8:395-402.
11. Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2:533-37.
12. Cooper JA, Miller GJ, Bauer KA et al. Comparison of novel haemostatic risk factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000;102:2816-22.
13. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41.
14. Rudnicka AR, Mt-Isa S, Meade TW. Associations of plasma fibrinogen and factor VII clotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention Trial. J Thromb Haemost 2006;4:2405-10.
15. Office of Population Census and Surveys (OPCS). Standard Occupational Classification. Vol. 3, London: HMSO, 1991.
16. World Health Organisation (WHO). Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, Eight, Ninth and Tenth Revisions. Geneva: WHO, 1967, 1977, 1994.
17. Fine J, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
18. Clayton D, Hills M. Statistical Models in Epidemiology. Oxford: Oxford University Press, 1993.
19. Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 2007;26:965-74.
20. Skrondal A, Rabe-Hesketh S. Generalized Latent Variable Modelling: Multilevel, Longitudinal, and Structural Equation Models. Boca Raton, FL: Chapman & Hall/CRC, 2004.
21. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM. Measurement Error in Nonlinear Models. 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 2006.
22. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
23. Heikkilä K, Harris R, Love G et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20:15-26.
24. Miller GJ, Bauer KA, Howarth DJ et al. Increased evidence of neoplasia of the digestive tract in men with persistent activation of the coagulation pathway. J Thromb Haemost 2004;2:2107-14.
25. Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The Hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4:465-73.
26. Dotsenko O, Kakkar K. Thrombosis and cancer. Ann Oncol 2006;17(Suppl 10):x81-84.
27. Palumbo JS, Kombrinck KW, Drew AF et al. Fibrinogen is an important determinant of metastatic potential of circulating tumour cells. Blood 2000;96:3302-9.
28. Palumbo JS, Talmage KE, Massari JV et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumour cells. Blood 2005;105:178-85.
29. Pignatelli B, Li C-Q, Boffetta P et al. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001;61:778-84.
30. Davey Smith G, Ebrahim S. "Mendelian Randomisation": can genetic epidemiology contribute to the understanding of environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
31. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: 1849-61.